Skip to content

Abstract 10298: Comparative Outcomes of Transcatheter Tricuspid Edge-to-Edge Repair versus Transcatheter Tricuspid Valve Replacement: A Propensity-Matched Real-World Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Transcatheter therapies for severe tricuspid regurgitation (TR) have rapidly expanded, with transcatheter tricuspid edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) emerging as major treatment strategies. Comparative real-world outcome data between these approaches remain limited. Methods: We performed a retrospective cohort study using the TriNetX Global Collaborative Network including 171 healthcare organizations. Adult patients undergoing T-TEER or TTVR were identified using CPT and ICD-10-PCS procedural codes. Propensity score matching (1:1) was performed using 48 variables, including demographics, comorbidities, medications, and laboratory characteristics including left ventricular ejection fraction. The primary outcome was heart failure hospitalization (HFH). Secondary outcomes included stroke, permanent pacemaker implantation, infective endocarditis, and new dialysis requirement after the index procedure. Kaplan-Meier and risk analyses were performed. Results: A total of 2,351 patients were identified, including 1,337 undergoing T-TEER and 1,014 undergoing TTVR. After propensity score matching, 901 patients remained in each cohort. Mean follow-up duration after matching was 851 days for T-TEER and 866 days for TTVR. The primary outcome of HFH occurred less frequently among patients undergoing T-TEER than TTVR (54 [19.1%] vs 72 [24.6%]), although this difference did not reach statistical significance (HR 0.72, 95% CI 0.51-1.03; p=0.069). Similarly, stroke rates were not significantly different between groups (54 [6.9%] vs 63 [7.7%]; HR 0.88, 95% CI 0.61-1.26; p=0.479). However, T-TEER was associated with significantly lower risks of permanent pacemaker implantation (27 [3.5%] vs 81 [11.4%]; HR 0.29, 95% CI 0.19-0.45; p=0.014) and infective endocarditis (21 [2.4%] vs 61 [7.4%]; HR 0.33, 95% CI 0.19-0.52; p<0.001). Rates of new dialysis requirement were similar between groups (24 [2.8%] vs 28 [3.2%]; HR 0.85, 95% CI 0.49-1.46; p=0.135). Conclusions: In this large propensity-matched real-world analysis, T-TEER and TTVR demonstrated comparable risks of HF hospitalization, stroke, and dialysis. However, T-TEER was associated with lower risks of permanent pacemaker implantation and infective endocarditis. These findings may help inform procedural selection and patient counseling as transcatheter tricuspid interventions continue to expand.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.